GlassScriptPhysician profile
Shaun K Joshi
NPI 1073629150
$4,763.09
in general payments reported to CMS, 2019-2025
27 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $451 · 2021: $489 · 2022: $617 · 2023: $520 · 2024: $811 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736 · Consulting Fee: $400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $47.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.44 |
| Consulting Fee | $400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $47.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $650.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $537.30 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $534.57 | 2019-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $366.67 | 2019-2025 | Ultomiris |
| Amgen INC. | $362.41 | 2019-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $321.84 | 2024 | |
| Glaxosmithkline, LLC. | $235.46 | 2021-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $203.99 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $193.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $192.54 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $187.92 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $180.48 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $153.86 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $141.20 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $110.25 | 2023-2025 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $80.82 | 2019 | |
| Ardelyx, INC. | $67.40 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $51.76 | 2022-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $40.28 | 2022-2024 | Terlivaz |
| Allergan, INC. | $29.99 | 2020 | |
| Recordati_rare_diseases_inc. | $25.40 | 2024 | Cystadrops |
| Cormedix INC. | $22.86 | 2024 | Defencath |
| Exact Sciences Corporation | $17.99 | 2025 | The Cologuard Plus Collection Kit |
| Fresenius USA Marketing, INC. | $15.21 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.76 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.10 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.